This document discusses the use and impact of EULabCap monitoring in Austria. It notes that unlike many EU countries, Austria did not require clinical microbiology laboratories to be licensed or obtain biosafety authorization, and there was no monitoring of diagnostic testing guidelines for key diseases. Contribution of national reference laboratories to national surveillance varied by disease and was below the EU average. Molecular typing data on pilot pathogens were no longer reported to the EU surveillance database and antimicrobial resistance characterization was only performed upon request, not as part of monitoring surveys. Overall compliance with EU standards was lower than most other EU nations.